- Issuer ticker
-
STOK
- Reported as of
-
03 Jun 2026
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
4 source fields
- SEC form
-
4
- Accepted by SEC
-
05 Jun 2026, 16:31:41 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Jonathan Allan, Attorney-in-Fact
Key filing fact
Julie Smith filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 05 Jun 2026.
Key facts
- This page summarizes Julie Smith's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jun 2026, 16:31.
Change
- Previous filing in this sequence was filed on 29 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001557928
Primary reporting owner
Smith Julie
- Relationship
-
Director
- Address
- C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD
- Signature
- /s/ Jonathan Allan, Attorney-in-Fact
- Signature date
- 05 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
STOK
transaction
Derivative
Director Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +17,786
- Change %
- Price
-
$0.000000*
- Shares after
- 17,786
- Date
- 03 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,786
- Exercise price
- $29.46
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote